The TRIP from ULF to ARF.
ARF is a key activator of p53, and together they form a critical duo for protection against cancer. Previous evidence had recognized the regulatory potential of ubiquitin-mediated degradation of ARF. The recent identification of TRIP12/ULF as a ubiquitin ligase of ARF adds an important missing piece to the ARF/p53 pathway.
Collado
Manuel
M
Tumour Suppression Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. mcollado@cnio.es
Serrano
Manuel
M
D020823:ADP-Ribosylation Factor 1 / Q000378:metabolism*; D020727:ADP-Ribosylation Factors / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D017209:Apoptosis; D002453:Cell Cycle; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000378:metabolism; D005091:Exons; D019942:Genes, p16; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000235:genetics / Q000473:pathology / Q000517:prevention & control; D009857:Oncogenes / Q000502:physiology; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*; D044767:Ubiquitin-Protein Ligases / Q000378:metabolism; D014452:Ubiquitins / Q000378:metabolism
D019941:Cyclin-Dependent Kinase Inhibitor p16; D016159:Tumor Suppressor Protein p53; D014452:Ubiquitins; D044767:Ubiquitin-Protein Ligases; D020823:ADP-Ribosylation Factor 1; D020727:ADP-Ribosylation Factors